State Street Corp Arcutis Biotherapeutics, Inc. Transaction History
State Street Corp
- $2.59 Trillion
- Q2 2025
A detailed history of State Street Corp transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 4,526,937 shares of ARQT stock, worth $76.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,526,937
Previous 4,474,203
1.18%
Holding current value
$76.6 Million
Previous $70 Million
9.3%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding ARQT
# of Institutions
240Shares Held
129MCall Options Held
407KPut Options Held
216K-
Suvretta Capital Management, LLC New York, NY11.5MShares$195 Million5.56% of portfolio
-
Jennison Associates LLC11.1MShares$188 Million0.09% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$182 Million3.47% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.87MShares$167 Million7.3% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$146 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $1.02B
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...